UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020799
Receipt number R000024012
Scientific Title Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritis
Date of disclosure of the study information 2016/02/01
Last modified on 2019/01/30 10:30:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritis

Acronym

Infliximab as a second Bio

Scientific Title

Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritis

Scientific Title:Acronym

Infliximab as a second Bio

Region

Japan


Condition

Condition

Rheumatoid arthritis

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Efficacy of Infliximab as a second Bio

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

DAS28

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients with rheumatoid arthritis treated with only one bio except for infliximab
more than 3.2 in DAS28-ESR
patients with

Key exclusion criteria

contraindication of infliximab and methotorexate
pregnant women
nursing women

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tatsuya Atsumi

Organization

Hokkaido University Hospital

Division name

Medicine II

Zip code


Address

N14W5 Kita-ku Sapporo

TEL

011-706-5915

Email

at3tat@med.hokudai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toshiyuki Bohgaki

Organization

Hokkaido University Hospital

Division name

Medicine II

Zip code


Address

N14W5 Kita-ku Sapporo

TEL

011-706-5915

Homepage URL


Email

tbohgaki@huhp.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University Hospital, Medicine II

Institute

Department

Personal name



Funding Source

Organization

Mitsubishi Tanabe Pharma Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 01 Month 19 Day

Date of IRB


Anticipated trial start date

2016 Year 01 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

patients with rheumatoid arthritis fulfilled with inclusion and exclusion criteria


Management information

Registered date

2016 Year 01 Month 29 Day

Last modified on

2019 Year 01 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024012


Research Plan
Registered date File name
2019/01/30 [No.014-0275]研究計画書【150119承認】 -改訂170729.pdf

Research case data specifications
Registered date File name

Research case data
Registered date File name